Steady progress in medical reform policies Biopharmaceutical demand is still rising

On the 6th, Premier Wen Jiabao pointed out in his 2011 work review that he actively and steadily promoted the reform and development of the medical and health care industry. The coverage of basic medical insurance continued to expand, with 1.3 billion urban and rural residents participating in insurance, and the universal health insurance system was initially formed. The proportion of inpatient expenses reimbursed within the scope of the policy has been increased, and the scope of medical care for major diseases has been further expanded.

The subsidy standards for financial insurance for urban residents and new rural cooperative medical insurance at all levels are raised from 120 yuan per person per year to 200 yuan. The national basic drug system is fully covered by government-run grass-roots medical and health institutions, and basic drug safety is improved and prices are falling. The reform of public hospitals was conducted in an orderly manner. The basic medical and health service system was basically completed. New progress has been made in the equalization of basic public health services.

At the same time, Minister of Health Chen Hao also said that by 2020, the nationwide medical insurance will be coordinated. The reform of the medical and health system will continue.

It is reported that in 2011, the pharmaceutical manufacturing industry realized revenue of 145.22 billion yuan, and the growth rate of revenue remained high, and the market capacity further increased. The consolidated gross profit margin was 28.90%, which was the lowest point in the past five years. In December, the gross profit margin rebounded but remained low.

Regarding the development of the pharmaceutical industry, Guohai Securities stated that if the pharmaceutical industry is considered as a non-cyclical industry, it shows better defensive characteristics at the bottom of the economic cycle, and the demand for medicines is still rising. Performance is more persistent and certainty than In the cyclical industry, the adjustment of stock prices gradually returns the industry valuation level to reasonable returns. Maintaining the previous judgment, the attitude of pharmaceutical stocks has gradually shifted from pessimistic to neutral, further observing the effect of industrial policy control and the company’s countermeasures, and maintaining the “neutral” judgment of the pharmaceutical industry, but for those companies with funds, technology, and brand In terms of the current stage, it has shown good investment value and it is recommended to actively participate.